European Society of Cardiology (ESC) formally accepts an abstract incorporating the latest data from MICRO, the first trial to explore magnetocardiography’s ability to diagnose microvascular dysfunction
June 23,2023, 8:00 AM ET
MASON, Ohio – Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that results from the Magnetocardiography as a Noninvasive Diagnostic Strategy for Suspected Coronary Microvascular Dysfunction trial, informally known as MICRO, will be presented as an abstract at the upcoming ESC Congress 2023. The annual conference held by the European Society of Cardiology will be in Amsterdam on August 25-28.
The full results will be held under embargo until the formal presentation, titled “Diagnosis of coronary microvascular dysfunction using magnetocardiography”. Data will be presented by the lead Principal Investigator on MICRO, Dr. Odayme Quesada, M.D., Medical Director of the Women’s Heart Center at The Christ Hospital Health Network. The presentation is part of a larger session named “Diagnostic and imaging methods in coronary artery disease”, which is scheduled for 10:15-11:00 AM on August 26.
The CorMicA study recently demonstrated that targeted treatment for patients diagnosed with coronary microvascular dysfunction (CMD) results in significantly improved quality of life. Unfortunately, conventional stress testing – with or without imaging – is neither sensitive nor specific for detecting this dysfunction. The current gold standard for diagnosis is either non-invasive interrogation by cardiac PET or invasive interrogation by functional angiography. These modalities are currently limited by availability, cost, and increased risk (either from radiation exposure or associated risk from invasive testing).
The MICRO trial, the first known trial to examine magnetocardiography’s (MCG) utility in diagnosing CMD, compared the performance of CardioFlux MCG to a gold standard of invasively measured coronary flow reserve (CFR) in patients with suspected ischemia and no evidence of obstructed coronary arteries(INOCA).
Led by Drs. Quesada and Henry from The Christ Hospital Health Network, Drs. Ziada and Cho from Cleveland Clinic, and Dr. Daher from Ascension St. John Hospital, the goal of MICRO was to explore and validate MCG as a rapid, safe, and completely non-invasive diagnostic modality for assessing INOCA patients. Participants received an MCG scan during normal course of care, and physicians who interpreted MCG scans were blinded to both the patients and their invasive angiographies.
“I know I speak for my entire team when I say it’s a privilege and an honor for us to be working with some of the brightest minds in CMD,” said Robert Takla, M.D., Chief Medical Officer at Genetesis.
Genetesis will be attending ESC in-person and can be found at booth C100. Conference participants are encouraged to visit the booth to discuss the results of MICRO in more detail.
To support a new, ischemia-first paradigm that can address the full spectrum of ischemic heart disease, Genetesis, Inc. is actively developing their flagship device, CardioFlux MCG. Based on the principles of magnetocardiography (MCG), CardioFlux MCG is a ground-breaking imaging solution with the potential to provide patients and physicians with a functional assessment of myocardial ischemia – including the ability to independently assess microvascular function – all within a completely non-invasive, 90-second scan that requires zero exercise, stress, or radiation.
Based in Mason, Ohio, Genetesis has been working to redefine the way ischemic heart disease is detected and understood since 2013. For more information, visit https://www.genetesis.com.
Ryan Yoo
Director of Product Marketing
ryan.yoo@genetesis.com